271 related articles for article (PubMed ID: 20680271)
41. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
42. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.
Cichocki F; Zhang B; Wu CY; Chiu E; Day A; O'Connor RS; Yackoubov D; Simantov R; McKenna DH; Cao Q; Defor TE; Janakiram M; Wangen R; Cayci Z; Snyder N; Kumar A; Grzywacz B; Hwang J; Geffen Y; Miller JS; Maakaron J; Bachanova V
Sci Transl Med; 2023 Jul; 15(705):eade3341. PubMed ID: 37467318
[TBL] [Abstract][Full Text] [Related]
43. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
44. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
[TBL] [Abstract][Full Text] [Related]
45. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
46. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
47. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
Rousseau RF; Haight AE; Hirschmann-Jax C; Yvon ES; Rill DR; Mei Z; Smith SC; Inman S; Cooper K; Alcoser P; Grilley B; Gee A; Popek E; Davidoff A; Bowman LC; Brenner MK; Strother D
Blood; 2003 Mar; 101(5):1718-26. PubMed ID: 12406881
[TBL] [Abstract][Full Text] [Related]
48. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
49. Treatment of patients with advanced cancer with the natural killer cell line NK-92.
Tonn T; Schwabe D; Klingemann HG; Becker S; Esser R; Koehl U; Suttorp M; Seifried E; Ottmann OG; Bug G
Cytotherapy; 2013 Dec; 15(12):1563-70. PubMed ID: 24094496
[TBL] [Abstract][Full Text] [Related]
50. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
51. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2.
Ozerol I; Ageitos A; Heimann DG; Talmadge JE
Int J Immunopharmacol; 1999 Aug; 21(8):509-21. PubMed ID: 10458540
[TBL] [Abstract][Full Text] [Related]
52. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
53. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.
Shapiro RM; Birch GC; Hu G; Vergara Cadavid J; Nikiforow S; Baginska J; Ali AK; Tarannum M; Sheffer M; Abdulhamid YZ; Rambaldi B; Arihara Y; Reynolds C; Halpern MS; Rodig SJ; Cullen N; Wolff JO; Pfaff KL; Lane AA; Lindsley RC; Cutler CS; Antin JH; Ho VT; Koreth J; Gooptu M; Kim HT; Malmberg KJ; Wu CJ; Chen J; Soiffer RJ; Ritz J; Romee R
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35349491
[TBL] [Abstract][Full Text] [Related]
54. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
55. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.
Rizzieri DA; Storms R; Chen DF; Long G; Yang Y; Nikcevich DA; Gasparetto C; Horwitz M; Chute J; Sullivan K; Hennig T; Misra D; Apple C; Baker M; Morris A; Green PG; Hasselblad V; Chao NJ
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1107-14. PubMed ID: 20188202
[TBL] [Abstract][Full Text] [Related]
56. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy.
Reittie JE; Gottlieb D; Heslop HE; Leger O; Drexler HG; Hazlehurst G; Hoffbrand AV; Prentice HG; Brenner MK
Blood; 1989 Apr; 73(5):1351-8. PubMed ID: 2495037
[TBL] [Abstract][Full Text] [Related]
57. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
58. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A
Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379
[TBL] [Abstract][Full Text] [Related]
59. Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.
Velilla PA; Shata MT; Lages CS; Ying J; Fichtenbaum CJ; Chougnet C
AIDS Res Hum Retroviruses; 2008 Jan; 24(1):52-61. PubMed ID: 18275348
[TBL] [Abstract][Full Text] [Related]
60. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
Duggan DB; Santarelli MT; Zamkoff K; Lichtman S; Ellerton J; Cooper R; Poiesz B; Anderson JR; Bloomfield CD; Peterson BA
J Immunother (1991); 1992 Aug; 12(2):115-22. PubMed ID: 1504052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
